• Je něco špatně v tomto záznamu ?

Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes

JH. Dalle, A. Balduzzi, P. Bader, A. Lankester, I. Yaniv, J. Wachowiak, A. Pieczonka, M. Bierings, A. Yesilipek, P. Sedlaçek, M. Ifversen, S. Sufliarska, J. Toporski, E. Glogova, U. Poetschger, C. Peters,

. 2018 ; 24 (9) : 1848-1855. [pub] 20180514

Jazyk angličtina Země Spojené státy americké

Typ dokumentu historické články, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035238

Allogeneic hematopoietic stem cell transplantation (HSCT) is beneficial for pediatric patients with relapsed or (very) high-risk acute lymphoblastic leukemia (ALL) in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007 I-BFM study and were stratified according to relapse risk (standard versus high versus very high risk of relapse) and donor type (matched sibling versus matched donor versus mismatched donor). A total of 148 patients (60% boys; median age, 8.7 years; B cell precursor ALL, 75%) were transplanted from mismatched donors, which was defined as either less than 9/10 HLA-compatible donors or less than 5/6 unrelated cord blood after myeloablative conditioning regimen (total body irradiation based, 67%) for high relapse risk (HRR; n = 42) or very HRR (VHRR) disease (n = 106). The stem cell source was either bone marrow (n = 31), unmanipulated peripheral stem cells (n = 28), T cell ex vivo depleted peripheral stem cells (n = 59), or cord blood (n = 25). The median follow-up was 5.1 years. The 4-year rates of overall survival (OS) and event-free survival were 56% ± 4% and 52% ± 4%, respectively, for the entire cohort. Patients transplanted from mismatched donors for HRR disease obtained remarkable 4-year OS and event-free survival values of 82% ± 6% and 80% ± 6%, respectively, whereas VHRR patients obtained values of 45% ± 5% and 42% ± 5% (P < .001), respectively. The cumulative incidence of relapse was 29% ± 4% and that of nonrelapse mortality 19% ± 3%. The cumulative incidence of limited and extensive chronic graft-versus-host disease was 13% ± 3% and 15% ± 4%, respectively, among the 120 patients living beyond day 100. Multivariate analysis showed that OS was lower for transplanted VHRR patients (P = .002; hazard ratio [HR], 3.62; 95% confidence interval [CI], 1.60 to 8.20) and for patients beyond second complete remission (CR2) versus first complete remission (P < .001; HR, 3.68; 95% CI, 1.79 to 7.56); relapse occurred more frequently in patients with VHRR disease (P = .026; HR, 3.30; 95% CI, 1.16 to 9.60) and for those beyond CR2 (P = .005; HR, 4.16; 95% CI, 1.52 to 10.59). Nonrelapse mortality was not significantly higher for cytomegalovirus-positive recipients receiving cytomegalovirus-negative grafts (P = .12; HR, 1.96; 95% CI, .84 to 4.58). HSCT with a mismatched donor is feasible in pediatric ALL patients but leads to inferior results compared with HSCT with better matched donors, at least for patients transplanted for VHRR disease. The results are strongly affected by disease status. The main cause of treatment failure is still relapse, highlighting the urgent need for interventional strategies after HSCT for patients with residual leukemia before and/or after transplantation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035238
003      
CZ-PrNML
005      
20191011084259.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbmt.2018.05.009 $2 doi
035    __
$a (PubMed)29772352
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dalle, Jean-Hugues $u Department of Pediatric Hemato-Immunology, Hôpital Robert Debré and Paris-Diderot University, Paris, France. Electronic address: jean-hugues.dalle@aphp.fr.
245    10
$a Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes / $c JH. Dalle, A. Balduzzi, P. Bader, A. Lankester, I. Yaniv, J. Wachowiak, A. Pieczonka, M. Bierings, A. Yesilipek, P. Sedlaçek, M. Ifversen, S. Sufliarska, J. Toporski, E. Glogova, U. Poetschger, C. Peters,
520    9_
$a Allogeneic hematopoietic stem cell transplantation (HSCT) is beneficial for pediatric patients with relapsed or (very) high-risk acute lymphoblastic leukemia (ALL) in remission. A total of 1115 consecutive patients were included in the ALL SCT 2003 BFM study and the ALL SCT 2007 I-BFM study and were stratified according to relapse risk (standard versus high versus very high risk of relapse) and donor type (matched sibling versus matched donor versus mismatched donor). A total of 148 patients (60% boys; median age, 8.7 years; B cell precursor ALL, 75%) were transplanted from mismatched donors, which was defined as either less than 9/10 HLA-compatible donors or less than 5/6 unrelated cord blood after myeloablative conditioning regimen (total body irradiation based, 67%) for high relapse risk (HRR; n = 42) or very HRR (VHRR) disease (n = 106). The stem cell source was either bone marrow (n = 31), unmanipulated peripheral stem cells (n = 28), T cell ex vivo depleted peripheral stem cells (n = 59), or cord blood (n = 25). The median follow-up was 5.1 years. The 4-year rates of overall survival (OS) and event-free survival were 56% ± 4% and 52% ± 4%, respectively, for the entire cohort. Patients transplanted from mismatched donors for HRR disease obtained remarkable 4-year OS and event-free survival values of 82% ± 6% and 80% ± 6%, respectively, whereas VHRR patients obtained values of 45% ± 5% and 42% ± 5% (P < .001), respectively. The cumulative incidence of relapse was 29% ± 4% and that of nonrelapse mortality 19% ± 3%. The cumulative incidence of limited and extensive chronic graft-versus-host disease was 13% ± 3% and 15% ± 4%, respectively, among the 120 patients living beyond day 100. Multivariate analysis showed that OS was lower for transplanted VHRR patients (P = .002; hazard ratio [HR], 3.62; 95% confidence interval [CI], 1.60 to 8.20) and for patients beyond second complete remission (CR2) versus first complete remission (P < .001; HR, 3.68; 95% CI, 1.79 to 7.56); relapse occurred more frequently in patients with VHRR disease (P = .026; HR, 3.30; 95% CI, 1.16 to 9.60) and for those beyond CR2 (P = .005; HR, 4.16; 95% CI, 1.52 to 10.59). Nonrelapse mortality was not significantly higher for cytomegalovirus-positive recipients receiving cytomegalovirus-negative grafts (P = .12; HR, 1.96; 95% CI, .84 to 4.58). HSCT with a mismatched donor is feasible in pediatric ALL patients but leads to inferior results compared with HSCT with better matched donors, at least for patients transplanted for VHRR disease. The results are strongly affected by disease status. The main cause of treatment failure is still relapse, highlighting the urgent need for interventional strategies after HSCT for patients with residual leukemia before and/or after transplantation.
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a dějiny 21. století $7 D049674
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a akutní lymfatická leukemie $x patologie $x terapie $7 D054198
650    _2
$a rizikové faktory $7 D012307
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nepříbuzný dárce $7 D061349
655    _2
$a historické články $7 D016456
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Balduzzi, Adriana $u Clinica Pediatrica, Università degli Studi di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy.
700    1_
$a Bader, Peter $u Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
700    1_
$a Lankester, Arjan $u Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, Netherlands.
700    1_
$a Yaniv, Isaac $u The Raina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
700    1_
$a Wachowiak, Jacek $u Department of Pediatric Oncology, Hematology and HSCT, Poznan University of Medical Sciences, Poznan, Poland.
700    1_
$a Pieczonka, Anna $u Department of Pediatric Oncology, Hematology and HSCT, Poznan University of Medical Sciences, Poznan, Poland.
700    1_
$a Bierings, Marc $u Department of Hematology, University Hospital of Children, Utrecht, Netherlands.
700    1_
$a Yesilipek, Akif $u Pediatric Stem Cell Transplantation Unit, Medical Park Antalya Hospital, Antalya, Turkey.
700    1_
$a Sedlaçek, Petr $u Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Ifversen, Marianne $u Paediatric Clinic II, Rigshospitalet, Copenhagen, Denmark.
700    1_
$a Sufliarska, Sabina $u Department of Paediatric Haematology and Oncology, Haematopoietic Stem Cell Transplantation Unit, Comenius University Children's Hospital, Bratislava, Slovakia.
700    1_
$a Toporski, Jacek $u Department of Hematology, Skanes University Hopsital, Lund, Sweden.
700    1_
$a Glogova, Evgenia $u St. Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria.
700    1_
$a Poetschger, Ulrike $u St. Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria.
700    1_
$a Peters, Christina $u St. Anna Children's Hospital, Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien, Vienna, Austria.
773    0_
$w MED00008579 $t Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation $x 1523-6536 $g Roč. 24, č. 9 (2018), s. 1848-1855
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29772352 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011084718 $b ABA008
999    __
$a ok $b bmc $g 1451898 $s 1073788
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 24 $c 9 $d 1848-1855 $e 20180514 $i 1523-6536 $m Biology of blood and marrow transplantation $n Biol Blood Marrow Transplant $x MED00008579
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace